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Abstract. The inception of World Trade Organization (WTO) in 1995 was expected to 
reduce trade barriers across member countries on one hand and facilitate growth though 
promotion of international trade in merchandise products and services on the other. The 
subsequent WTO-led reforms deepened the globalization wave. In recent times however, 
the world is witnessing a phase of ‘de-globalization’, with rise in trade barriers and 
inwardness. The recent increase in US tariffs on Chinese exports and countermeasures 
imposed by China are a case in point. In 2014 India has initiated the Make-in-India scheme 
for deepening industrialization and facilitating exports. The current paper evaluates the 
possible opportunities for expanding Indian pharmaceutical exports in the US market, given 
the increase in tariff against Chinese products with the help of select trade indices. The 
analysis portrays a modest opportunity for Indian pharmaceutical exports in the US market, 
based on their past performance. Only six products at HS 6-digit level, based on the six 
indicators, are found to be enjoying competitiveness in the US market. The paper concludes 
that facilitating R&D in pharma segment as well as expanding the coverage of mutual 
recognition of standards in US may be explored as possible steps for enhancing Indian 
exports. 
Keywords. India, US, Pharmaceutical trade, Trade indices, Trade policy, Make in India. 
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1. Introduction 
he inception of World Trade Organization (WTO) in 1995 was expected to 
reduce trade barriers across member countries on one hand and facilitate 
growth though promotion of international trade in merchandise products and 
services on the other. The subsequent WTO-led reforms deepened the globalization 
wave in the next two decades. In recent times however, the world is witnessing a 
phase of ‘de-globalization’, with rise in trade barriers and inwardness (James, 
2017). The backlash towards globalization can be explained by the undercurrent of 
several factors. First, slow progress of the Doha round of negotiations since 2001 
have lowered the attraction of the multilateral trade reform process to a major 
extent. The deadlock at the multilateral forum occur primarily due to the 
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differences between developed and developing countries over key reform agendas 
(Fergusson, 2011). Second, faster resolution of tariff and other non-tariff barriers 
(NTBs) reforms have enhanced the role of regional trade agreements (RTAs) as a 
trade-promotion route (Neufeld, 2014). It has further been noted that trade 
facilitation measures are instrumental in strengthening participation in Global 
Value Chains (GVCs) and International Production Networks (IPNs) (Shepherd, 
2016). Hence over the last decade a number of RTAs have implemented trade 
facilitation measures, investment agreement, mutual recognition agreements 
(MRAs) on technical standards etc. within their fold (Horn et al., 2009). However, 
freer trade within the RTAs have lowered the incentive for countries to proactively 
commit at the WTO forums, and thereby threatened the multilateral negotiation 
process (Baldwin, 2014). Finally, the declining growth projections in the time of 
recession (IMF, 2018) has fueled the protectionist mindsets, in line with past trends 
(Baldwin & Evenett, 2009).  
Since 1995, the US has participated aggressively in the WTO negotiation 
process and often pushed the developing countries for undertaking reform 
commitments within their territories. For instance, manufacturing subsidy reforms 
in China has been a major agenda for the country (CTI, undated). However, in the 
recent period the US policies have been increasingly influenced by the domestic 
defensive compulsions. For instance, the pullout from Trans-Pacific Partnership 
(TPP) in 2017 (Helble, 2017) and the rhetoric even against the North American 
Free Trade Agreement (NAFTA) partners like Mexico (Deeds and White ford, 
undated) deserve mention. While the rising protectionism in US can be part 
explained by electoral politics, perceptions on prevalence of WTO-incompatible 
trade policies in developing countries is another major driver (Lim, 2018). While 
the mindset change has been questioned within US (Lincicome, 2017), it is felt that 
the protectionist inclination would be in place there for some time.  
While the US has raised voice against policies of several trade partners (e.g., 
Mexico, Russia), its intervention on Chinese products has by far been most harsh. 
In June 2018, the US Trade Representative (USTR) announced increased tariff on a 
wide range of Chinese exports to US worth $50 billion. The trade war was further 
escalated with subsequent announcement on increased tariffs on Chinese imports 
worth another$200 billion. The covered items facing 25 percent duty include both 
low and high tech manufacturing products (USTR, 2018). In retaliation, the 
Chinese government imposed countermeasures, covering American exports of 
meat, seafood, grains, alcohol, tobacco etc. with a trade value of $60 billion, where 
the duties were increased between 5-10 percent (DW, 2018). It is noted that 
continuation of such trade wars would lead to significant losses for countries 
subjected to such measures (Bouet & Laborde, 2017).  
In 2014 India has initiated a drive towards deepened industrialization (Make-in-
India) by both attracting foreign multinationals to produce in India and by 
improving the Doing Business indicators and enabling the domestic players to 
participate in GVCs and IPNs. The sectors covered under this initiative includes 
both medium (e.g., food processing, leather, textile and garments) and high tech 
manufacturing sectors (e.g., auto-components, aviation, defense manufacturing, 
electronic and electrical machinery, pharmaceuticals). The country is also 
increasingly focusing for RTA route and newer opportunities for export promotion 
(Chakraborty, 2018). Therefore a prolonged trade war between China and US may 
provide Indian manufacturing exports a greater foothold in the US market for key 
manufacturing products.  
In this background, the current paper evaluates the possible opportunities for 
expanding Indian exports in the US market by bridging the possible gap emerging 
due to the trade war between the US and China. It is observed from Table 1 that the 
USTR tariff impositions on China are spread over 10 HS chapters. In the Table the 
count of products at disaggregated level under the 10 HS chapters are noted, along 
with the number of Indian export items. The third column shows the degree of 
commonality between the US measures on China and possible Indian export items. 
Journal of Economics Bibliography 
JEB, 5(4), D. Chakraborty, S. Maheshwari, & S. Parashar, p.209-222. 
211 
A higher number implies opportunities for Indian exports in US, as the 
corresponding Chinese products are witnessing higher import tariff against them. 
In the last column, the percentage share of India in world exports across the HS 
chapters are noted. 
 
Table 1. Count of sanctioned products 
 Source: Authors’ calculation based on Trade Map online database 
 
It is observed that for aircraft, spacecraft, and parts thereof (HS 88) and 
pharmaceutical products (HS 30) the ratio is 94 percent and 76 percent 
respectively, underlining the opportunities for India in US market in these 
segments. However, in case of pharmaceutical products India contributes2.5 
percent to world exports as compared to 1.2 percent in case of aircraft, spacecraft, 
and parts thereof. Therefore the current paper focuses on assessing opportunities 
for pharmaceutical products in the US market. The analysis is arranged along the 
following lines. The introduction is followed by a brief discussion on Make in 
India initiative for Pharma sector and US imports in the same sector respectively. 
Then through a few well-known trade indices, the competitiveness of India’s 
pharma exports to US is commented upon. Finally, based on the findings, certain 
policy conclusions are drawn. 
 
2. Make-in-India initiative in wider policy context: Pharma 
sector 
In 2004, India formed the National Manufacturing Competitiveness Councilto 
promote the manufacturing sector competitiveness. In 2011, the ‘National 
Manufacturing Policy’ identified a number of sectors where through 
competitiveness enhancement India can deepen its presence in the world (GoI, 
2011a). Subsequently, the need for enhancing manufacturing exports were 
explored through policy initiatives (GoI, 2011b). In continuation, the ‘Make in 
India’ scheme was introduced in 2014 to attract investments, encourage innovation, 
enhance skill level and make India a global hub of manufacturing activities. The 
initiative focuses on 25 key sectors, which include - automobiles, aviation, 
chemicals, IT & BPM, pharmaceuticals, construction, defense manufacturing, 
electrical machinery, food processing, textiles and garments, ports, leather, media 
and entertainment, wellness, mining, tourism and hospitality, railways, automobile 
components, renewable energy, biotechnology, space, thermal power, roads and 
highways and electronics systems (GoI, undated).  
It is observed that pharma sector is in the reckoning of the policymakers 
consistently as a major contributor to both value addition and exports. The notable 
initiative under the ‘Make in India’ programme in this sector are visible through – 
reduction of coronary Stents price by 85 percent, launching of Pharma Jan 
Samadhan and Pharma SahiDaam, approval of 11 National Institutes of 
Pharmaceutical Education & Research (NIPERs) and so on (GoI, 2018). 
The pharma industry in India is 3rd largest in terms of volume and 10th largest in 
terms of value, thus contributing to around 10 percent of global production. The 
HS 
Code Description 
Count of 
total Make 
in India 
Products 
Count of 
tariff-facing 
Chinese 
Products 
Percent of 
Affected 
Products 
(%) 
India’s 
Percent Share 
in World 
Exports (%) 
28 Inorganic chemicals 273 4 1.5 1.2 
29 Organic chemicals 1111 38 3.4 3.1 
30 Pharmaceuticals 59 45 76.3 2.5 
73 Articles of Iron and Steel 254 44 17.3 2.3 
76 Aluminum and articles thereof 72 27 37.5 1.7 
85 Electrical machinery and equipment 641 241 37.6 0.4 
86 Railway and locomotives 32 17 53.1 0.5 
87 Vehicles and auto-components 218 47 21.6 1.1 
88 Aircraft, spacecraft, and parts thereof 17 16 94.1 1.2 
89 Ships, boats and floating structures 22 11 50.0 2.9 
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sector, which stood at US$ 16.4 billion in 2016-17, has contributed to 6 per cent of 
the country’s total exports (IBEF,2018). India is an exporter of both bulk drugs and 
formulations. It has also emerged as a major player in R&D services for global 
corporates, either through contracts or collaborative programmes (PWC, 2010). To 
facilitate technology transfer from abroad under Make in India, FDI in the 
pharmaceutical sector is allowed up to 100 percent through automatic route for 
manufacturing of medical devices. In addition, ‘Pharma Vision 2020’ has been 
introduced to make India a global leader in end-to-end drug manufacture (IBEF, 
2015), which would make India a drug discovery and innovation powerhouse 
through capacity creation at home. Focus is also given on encouraging 
indigenization of Active Pharmaceutical Ingredients (APIs) with a goal to lower 
their imports from China (ASSOCHAM, 2016).A concerted effort in this sphere is 
crucial because while the generic drug exports from the country is increasing, it’s 
reliance on China for import of raw materials is quite high (Kallummal and 
Bugalya, 2012). It has been noted that India’s global presence can be deepened 
further through coordinated policy efforts, namely - upgradation of quality systems, 
infrastructure creation, capability enhancement, move to create a brand for reliable, 
high-quality medicine supply, improving transparency and predictability of 
regulations and so on (FICCI, 2015).  
Apart from the direct influence of the ‘Make in India’ initiative, the pharma 
sector has received support from other government programmes as well. India’s 
Foreign Trade Policy(2015-20) was launched in 2015 with the objective to boost 
exports and establish India as a major player in global trade by 2020. The 
introduction of Merchandise Exports from India Scheme (MEIS) under the FTP 
(2015-20), which intends to ensure the competitiveness of Indian exports in partner 
countries through incentives in terms of duty credit scrip, provided a major boost to 
the pharmaceutical sector (GoI,2015). In addition, the ‘Make in India’ products are 
also entitled to public procurement policies (GoI,2017). At the broader canvas, the 
FTP instruments integrate with the Make in India initiative and other regulatory 
reforms to improve Ease of Doing Business in India, and thereby intensify 
manufacturing activities and exports.  
 
3. Comparing presence of China and India in US 
pharmaceutical imports 
According to IFPMA (2017), global pharmaceutical market is expected to reach 
USD 1.48 trillion by 2021, growing from USD 1.10 trillion in 2016, which can be 
explained by market expansion in emerging countries and ageing population 
growth in the developed countries. The growth of the global brand medicines and 
generics sales are forecasted to reach USD 815-832 billion and USD 495-505 
billion respectively by 2021. It is observed from Trade Map data that in global 
import of pharmaceutical products (HS 30), US’s share has significantly increased 
from 12.6 percent in 2013 to 17.2 percent in 2017. India on the other hand has 
emerged as one of the major exporters of generic drugs, accounting for 20 percent 
of the global demand. Indian medicines are now exported to almost all countries 
with US as the key market(IBEF, 2018).It is observed from Trade Map data that in 
global export of pharmaceutical products (HS 30), India’s share has increased 
marginally from 2.4 percent in 2013 to 2.5 percent in 2017.  
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Figure 1. Percent share in US Pharma imports (by value) 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
 
Figure 1 shows the shares of India and China in US pharmaceutical imports 
over the last decade. It is observed that the penetration of India in US market for 
this category has been deeper as compared to China throughout the period. While 
the share of China has stagnated around 1.5 percent since 2013, India has improved 
its share from a meagre 2.9 percent in 2008 to 6.5 percent in 2017, though over 
2016-17 a drop in the same has been noticed. The graph indicates growing 
recognition and consequent demand for Indian pharma products in US market.  
Table 2 displays the share of China and India in US import of pharmaceutical 
products by HS headings (4-digit). It is observed that while China is a major player 
in dried glands and other organs (HS 3001), wadding, gauze, bandages and the like 
(HS 3005) and pharmaceutical preparations and products (HS 3006), Indian 
exports are mostly concentrated in medicaments consisting of mixed or unmixed 
products(HS 3004), medicaments consisting of two or more constituents mixed 
together (HS 3003) and pharmaceutical preparations and products (HS 3006). It is 
observed that India’s average shares in US imports of HS 3003, 3004 and 3006 
have increased considerably during the recent period. In other words, a clearly 
demarked pattern of competitiveness of the two countries emerges from the US 
import analysis at the heading level.  
 
Table 2. US Imports by Value (USD 000 and Percent share) 
 
Description 
India China 
HS 
Code  
2008-12 2013-17 2008-12 2013-17 
3001 
Dried glands and other organs for 
organo-therapeutic uses etc. 
816 
(0.17) 
406 
(0.10) 
264772 
(56.28) 
176268 
(43.62) 
3002 
Human blood; animal blood 
prepared for therapeutic, 
prophylactic or diagnostic uses etc. 
6606 
(0.07) 
6629 
(0.37) 
23971.8 
(0.28) 
75099.2 
(0.42) 
3003 
Medicaments consisting of two or 
more constituents mixed together 
etc. 
27022 
(2.01) 
36443 
(4.01) 
36303.4 
(2.71) 
55192.8 
(6.07) 
3004 
Medicaments consisting of mixed 
or unmixed products etc. 
2625511 
(5.56) 
5782129 
(9.66) 
60943 
(0.12) 
269849 
(0.45) 
3005 
Wadding, gauze, bandages and the 
like 
195 
(0.02) 
4619 
(0.45) 
263320 
(34.62) 
391619 
(38.30) 
3006 
Pharmaceutical preparations and 
products 
4595 
(0.21) 
69132 
(2.70) 
168828 
(7.77) 
283980 
(11.10) 
Source: Authors’ calculation based on Trade Map (ITC, undated). 
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4. Methodology and data 
For the analysis, six well-known trade indices have been used for understanding 
India’s competitiveness in general and in the US market in particular, while 
comparing with the corresponding numbers for China. The following indices have 
been calculated at HS sub-heading level (6-digit). 
First, for understanding overall competitiveness of Indian exports, the Revealed 
Comparative Advantage (RCA) index has been computed by the following 
formula: 
 
𝑅𝐶𝐴𝑖 =
 𝐴𝑖𝑋  /  𝐴𝑋
 𝑊𝑖𝑋  /  𝑊𝑋
 
 
where,  𝐴𝑖𝑋 stands for export of a particular HS 6-digit product from country A 
(say, India),  𝐴𝑋stands for total exports from A,  𝑊𝑖𝑋 stands for exports of the 
product by all countries and  𝑊𝑋stands for total global exports. If the RCA index 
is higher than unity, then a country is said to possess comparative advantage in that 
product category. 
Second, for understanding whether Indian exports are increasingly moving 
towards a partner country, the Export Intensity Index (EII) has been computed by 
the following formula: 
 
𝐸𝐼𝐼𝐼𝑁𝐷 ,𝑗 =  
𝐼𝑁𝐷𝑗
𝑋 𝐼𝑁𝐷𝑊
𝑋 
𝑊𝑂𝑅𝑗
𝑋 𝑊𝑂𝑅𝑊
𝑋 
 
 
where, 𝐼𝑁𝐷𝑗
𝑋stands for a particular HS 6-digit product from India to country 
j(say, US), 𝐼𝑁𝐷𝑊
𝑋 stands for total exports of that product from India to all countries, 
𝑊𝑂𝑅𝑗
𝑋stands for total export of the HS 6-digit product from rest of the world to 
country j (or, import of the product by country j from rest of the world) and 𝑊𝑂𝑅𝑊
𝑋  
stands for total global export of the HS 6-digit product (or, total global export of 
the HS 6-digit product). If the EII index for India in a product category is found to 
be greater than unity, then it is said to be having an intensive export relationship 
with that partner for that product. 
Third, for understanding whether Indian exports are indeed deepening their 
presence in the imports of a partner country, Revealed Trade Barrier (RTB) index 
has been computed by the following formula: 
 
𝑅𝑇𝐵𝑃𝐴𝑅𝑇 ,   𝐼𝑁𝐷 =  
𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑖 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑇 
𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑖 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑇 
 
 
where, 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑖 stands for imports of a particular HS 6-digit product by trade 
partner (say, US) from India, 𝑃𝐴𝑅𝑇𝐼𝑁𝐷
𝑀𝑇 stands for total imports by partner country 
from India, 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑖 stands for imports of the HS 6-digit product by partner 
country from rest of the world and 𝑃𝐴𝑅𝑇𝑊𝑂𝑅
𝑀𝑇 stands for total imports by partner 
country from rest of the world. In case the RTB index is greater than unity, it might 
be noted that India is not facing many trade barriers in import relationship in the 
partner country. EII and RTB taken together can be considered as a measure of 
competitiveness of a product in a partner country market.  
Fourth, in case there is both-way trade between India and the partner country in 
a HS 6-digit level product, the emerging specialization can be checked with the 
Export Specialization Index (ESI), computed by the following formula:   
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𝐸𝑆𝐼𝑖𝑗 =  
𝐼𝑁𝐷𝑖𝑗
𝑋 𝐼𝑁𝐷𝑇𝑗
𝑋 
𝑃𝑅𝑇𝑖𝐼𝑁𝐷
𝑋 𝑃𝑅𝑇𝑇𝐼𝑁𝐷
𝑋 
 
 
where, 𝐼𝑁𝐷𝑖𝑗
𝑋stands for exports of a particular HS 6-digit product from India to 
country j (say, US), 𝐼𝑁𝐷𝑇𝑗
𝑋 stands for total exports from India to partner country, 
𝑃𝑅𝑇𝑖𝐼𝑁𝐷
𝑋  stands for exports of the particular product by partner country to 
India and 𝑃𝑅𝑇𝑇𝐼𝑁𝐷
𝑋 stands for total exports by partner country to India. In case the 
ESI index exceeds unity, India is said to be developing an export specialization 
with respect to the partner country. It can be confirmed by checking whether 
India’s export value is consistently greater than the corresponding import value, 
i.e., whether India enjoys a positive trade balance (TB) in that category.  
Finally, India’s nature of price competitiveness in a particular product category 
can be checked by computing the Unit Price Ratio (UPR) by the following 
formula: 
 
𝑈𝑃𝑅𝑖𝑗 =  
𝑈𝑉𝑖𝑗
𝑋
𝑈𝑉𝑖𝑗
𝑀  
 
where, 𝑈𝑉𝑖𝑗
𝑋stands for the unit value of India’s exports of a particular HS 6-digit 
product to country j (say, US) and 𝑈𝑉𝑖𝑗
𝑀stands for the unit value of India’s imports 
of that product from the partner country. If the UPR index exceeds unity, and India 
is enjoying positive trade balance as well as ESI greater than 1, it might occur due 
to better quality of Indian export, in line with the framework developed by Stiglitz 
(1987). Conversely, a UPR less than unity can coexist with positive trade balance 
and ESI greater than 1, if there is price competitiveness in favour of Indian exports. 
The data on trade values and unit prices for computing the indices used in the 
analysis has been accessed from the Trade Map database (ITC, undated). The last 
decade, i.e., 2008-17 has been considered as the period of analysis to identify the 
emerging trends, if any. In order to ensure that annual fluctuations do not influence 
the conclusions, five-year averages of the trade indices have been compared.  
 
5. Interpretation of trade indices 
The Indian competiveness scenario for the HS 6-digit codes under 
pharmaceuticals (HS 30) in both absolute and bilateral levels, are reported in Table 
3. From the first set of columns, it is observed that the average RCA for only seven 
products has been consistently above unity over the two periods considered in the 
analysis. In other words, India is enjoying competitiveness in export of these 
products in global scale. Second, comparing the average EII and RTB indices for 
India with respect to the US market for the corresponding time periods, it can be 
seen that the indices for these products are also above unity. It can therefore be 
noted that, India may benefit in these product categories in the US market as a 
result of the importing country increasing tariff against China therein. These 
product categories are: Medicaments containing hormones or steroids used as 
hormones (HS 300339), Medicaments consisting of two or more constituents 
mixed together (HS 300390), Medicaments containing penicillins or derivatives 
thereof with a penicillanic acid structure (HS 300410), Medicaments containing 
antibiotics, put up in measured doses (HS 300420), Medicaments containing 
provitamins, vitamins etc. (HS 300450), Medicaments consisting of mixed or 
unmixed products for therapeutic or prophylactic purposes (HS 300490) and 
Chemical contraceptive preparations based on hormones, prostaglandins, 
thromboxanes, leukotrienes etc. (HS 300660). As noted from Table 2, India already 
enjoys deepening presence in US market for the corresponding HS chapters.  
Table 4 depicts the corresponding scenario for China. It is noted from the table 
that only for Opacifying preparations for x-ray examinations; diagnostic reagents 
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for administration to patients (HS 300630), China enjoy an absolute 
competitiveness in global market (i.e., RCA greater than unity). The product group 
is observed to be enjoying bilateral competitiveness (i.e., both EII and RTB greater 
than unity)in the US market as well.  
Table 5 summarizes India’s bilateral competitiveness as reflected from the ESI, 
TB and UPR. It is seen that the first two conditions are favourable (i.e., ESI greater 
than unity, TB positive) for a total of nine product segments. The HS headings are 
– Extracts of glands or other organs or of their secretions, for organo-therapeutic 
uses (HS 300120), Medicaments containing antibiotics, not in measured doses or 
put up for retail sale (HS 300320), Medicaments containing insulin, not in 
measured doses or put up for retail sale (HS 300331), Medicaments containing 
hormones or steroids used as hormones (HS 300339), Medicaments consisting of 
two or more constituents mixed together (HS 300390), Medicaments containing 
penicillins or derivatives thereof with a penicillanic acid structure (HS 300410), 
Medicaments containing antibiotics, put up in measured doses (HS 300420), 
Medicaments containing provitamins, vitamins etc. (HS 300450) and Medicaments 
consisting of mixed or unmixed products for therapeutic or prophylactic purposes 
(HS 300490).Among the nine products, barring the exception of HS 300120 all 
other commodities have the UPR less than unity. In other words, India’s entry in 
the US market for these products might be backed by price competitiveness.  
The corresponding ESI, TB and UPR scenario for China has been shown with 
the help of Table 6. It is observed that only for Medicaments containing antibiotics, 
not in measured doses or put up for retail sale (HS 300320), the competitiveness 
conditions (i.e., ESI greater than unity, TB positive) are getting fulfilled. The UPR 
for the product is less than unity, indicating possible price competitiveness therein.  
Combining the two lists emerging from Tables 3 and 5, it can be seen that India 
is enjoying clear advantage in six product categories in the US market, namely – 
Medicaments containing hormones or steroids used as hormones (HS 300339), 
Medicaments consisting of two or more constituents mixed together (HS 300390), 
Medicaments containing penicillins or derivatives thereof with a penicillanic acid 
structure (HS 300410), Medicaments containing antibiotics, put up in measured 
doses (HS 300420), Medicaments containing provitamins, vitamins etc. (HS 
300450) and Medicaments consisting of mixed or unmixed products for therapeutic 
or prophylactic purposes (HS 300490). As noted from Table 2, India’s presence in 
US imports of HS 3003 and HS 3004 are already substantial. Based on the 
evidence from the indices, it appears that China might not offer significant 
competition to Indiain these six product categories in US market.  
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Table 3. Trade Indices for India in Pharmaceutical Products (HS Code 30) 
HS 
Code 
Revealed Comparative 
Advantage Export Intensity Index Revealed Trade Barrier 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300410 5.47 8.46 0.99 1.72 14.60 11.03 
300420 3.44 3.82 3.94 3.98 15.99 16.10 
300339 10.94 3.55 26.44 3.11 16.32 6.68 
300450 4.05 3.21 3.12 3.01 1.77 10.12 
300660 0.78 2.68 0.02 1.39 0.29 3.21 
300490 1.13 2.09 2.06 2.35 3.58 5.45 
300390 2.92 1.91 1.29 2.83 1.60 2.71 
300691 0.32 1.59 0.00 0.00 0.00 0.00 
300220 0.80 1.48 0.02 0.03 0.00 0.00 
300331 1.65 0.98 7269.83 2.04 22.52 0.20 
300320 5.98 0.98 1.17 0.45 0.81 1.07 
300670 0.77 0.95 1.06 0.05 0.01 0.00 
300431 0.65 0.88 1.79 0.69 0.01 0.00 
300120 0.76 0.55 5.57 22.77 2.54 1.31 
300610 0.29 0.34 0.07 0.12 0.04 0.11 
300630 0.06 0.20 0.33 0.44 0.00 0.21 
300439 0.25 0.20 0.99 1.04 0.81 0.76 
300290 0.38 0.19 0.49 0.60 0.20 0.08 
300640 0.23 0.16 1.17 1.33 0.09 0.03 
300230 0.13 0.13 0.05 0.35 0.05 0.01 
300432 0.04 0.12 0.00 0.52 0.03 0.42 
300510 0.12 0.09 0.12 0.10 0.01 0.00 
300620 0.05 0.03 4.75 0.00 0.20 1.37 
300212 0.00 0.00 0.00 0.00 0.00 0.00 
300215 0.00 0.00 0.00 0.00 0.00 0.00 
300449 0.00 0.00 0.00 0.00 0.00 0.00 
300219 0.00 0.00 0.00 0.00 0.00 0.00 
300211 0.00 0.00 0.00 0.00 0.00 0.00 
300213 0.00 0.00 0.00 0.00 0.00 0.00 
300214 0.00 0.00 0.00 0.00 0.00 0.00 
300341 0.00 0.00 0.00 0.00 0.00 0.00 
300342 0.00 0.00 0.00 0.00 0.00 0.00 
300349 0.00 0.00 0.00 0.00 0.00 0.00 
300360 0.00 0.00 0.00 0.00 0.00 0.00 
300441 0.00 0.00 0.00 0.00 0.00 0.00 
300442 0.00 0.00 0.00 0.00 0.00 0.00 
300460 0.00 0.00 0.00 0.00 0.00 0.00 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
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Table 4. Trade Indices for China in Pharmaceutical Products (HS Code 30) 
HS 
Code 
Revealed Comparative 
Advantage Export Intensity Index Revealed Trade Barrier 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300410 0.26 0.32 0.01 0.01 0.01 0.05 
300420 0.01 0.06 0.85 0.67 0.06 0.07 
300339 0.00 0.00 3.79 0.00 0.95 0.00 
300450 0.13 0.12 3.85 2.56 0.04 0.03 
300660 0.04 0.06 0.48 2.33 0.01 0.23 
300490 0.00 0.00 0.20 0.38 0.01 0.02 
300390 0.00 0.00 2.07 2.41 0.16 0.36 
300691 0.11 0.03 2.29 1.48 0.00 0.00 
300220 0.01 0.02 0.00 0.01 0.00 0.00 
300331 0.01 0.00 0.00 0.00 0.00 0.00 
300320 1.39 2.43 0.16 0.69 0.12 0.13 
300670 0.24 0.36 10.88 2.92 0.02 0.50 
300431 0.01 0.14 0.00 0.00 0.00 0.00 
300120 0.50 0.34 1.87 1.34 0.01 0.54 
300610 0.03 0.01 2.33 1.34 0.01 0.00 
300630 1.01 1.41 2.32 2.49 1.11 1.35 
300439 0.02 0.01 0.04 0.07 0.00 0.00 
300290 0.03 0.03 0.75 0.55 0.01 0.01 
300640 0.09 0.09 0.73 0.39 0.05 0.04 
300230 0.04 0.03 0.00 0.00 0.00 0.00 
300432 0.03 0.03 0.00 0.00 0.00 0.01 
300510 0.70 0.82 2.00 1.63 0.92 1.09 
300620 0.01 0.02 0.72 0.04 0.02 0.02 
300212 0.14 0.14 0.00 0.00 0.00 0.00 
300215 0.25 0.22 0.00 0.00 0.00 0.00 
300449 0.00 0.00 0.00 0.00 0.00 0.00 
300219 0.00 0.00 0.00 0.00 0.00 0.00 
300211 0.00 0.00 0.00 0.00 0.00 0.00 
300213 0.00 0.00 0.00 0.00 0.00 0.00 
300214 0.00 0.00 0.00 0.00 0.00 0.00 
300341 0.00 0.00 0.00 0.00 0.00 0.00 
300342 0.00 0.00 0.00 0.00 0.00 0.00 
300349 0.00 0.00 0.00 0.00 0.00 0.00 
300360 0.00 0.00 0.00 0.00 0.00 0.00 
300441 0.00 0.00 0.00 0.00 0.00 0.00 
300442 0.00 0.00 0.00 0.00 0.00 0.00 
300460 0.00 0.00 0.00 0.00 0.00 0.00 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
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Table 5.  Trade Indices for India in Pharmaceutical Products with USA (HS Code 30) 
Source: Authors’ calculation based on Trade Map (ITC, undated) 
  
HS Code 
Export Specialization Index Trade Balance Unit Price Ratio 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300331 863.01 907.32 1551 265 0.00 0.03 
300339 174.59 34.87 45475 2764 0.05 0.08 
300450 13.72 14.61 27756 19440 0.27 0.14 
300410 5.61 7.11 26120 128829 0.40 0.37 
300230 7.37 5.73 -2286 -3022 0.93 0.95 
300420 5.53 5.30 219750 338724 0.23 0.35 
300691 0.79 5.23 -71 -537 0.33 1.79 
300120 3.24 3.56 77 1434 0.38 1.62 
300390 2.48 3.28 63834 59596 0.19 0.34 
300320 7.27 2.15 7581 233 0.23 0.74 
300490 1.02 1.64 1279701 3509898 0.06 0.15 
300670 3.52 1.57 -191 -1206 0.65 2.21 
300220 1.05 1.20 -12868 -25946 0.08 0.06 
300660 0.46 0.94 -42 60476 0.12 0.11 
300610 0.54 0.55 -3058 -5050 0.18 0.09 
300431 0.28 0.28 31558 32671 0.15 0.03 
300640 0.16 0.12 -1791 -2116 0.25 0.10 
300630 0.03 0.11 -439 1102 0.70 1.03 
300439 0.15 0.11 7027 4351 0.03 0.05 
300510 0.12 0.09 -1058 -2042 0.27 0.30 
300432 0.02 0.06 2 2631 0.07 0.04 
300290 0.14 0.05 -2884 -9927 0.07 0.18 
300620 0.16 0.05 -270 -1285 0.27 0.16 
300212 0.00 0.00 0 -4245 0.00 0.09 
300215 0.00 0.00 0 -4749 0.00 0.03 
300449 0.00 0.00 0 724 0.00 0.02 
300219 0.00 0.00 0 -1098 0.00 0.16 
300211 0.00 0.00 0 -254 0.00 0.01 
300213 0.00 0.00 0 -707 0.00 0.00 
300214 0.00 0.00 0 1 0.00 0.00 
300341 0.00 0.00 0 0 0.00 0.02 
300342 0.00 0.00 0 0 0.00 0.00 
300349 0.00 0.00 0 0 0.00 0.06 
300360 0.00 0.00 0 0 0.00 1.14 
300441 0.00 0.00 0 0 0.00 0.06 
300442 0.00 0.00 0 0 0.00 0.03 
300460 0.00 0.00 0 0 0.00 0.00 
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Table 6. Trade Indices for China in Pharmaceutical Products with USA (HS Code 30) 
HS 
Code 
Export Specialization Index Trade Balance Unit Price Ratio 
2008-12 2013-17 2008-12 2013-17 2008-12 2013-17 
300331 59.43 0.09 0 0 0.00 0.00 
300339 0.04 0.01 15 -86 0.01 0.02 
300450 0.45 0.53 -20877 -41272 0.15 0.12 
300410 0.27 0.26 -14556 173 0.13 0.13 
300230 2.23 1.31 -61260 -176908 0.53 0.60 
300420 0.22 0.20 -102890 -124679 0.10 0.10 
300691 0.25 0.11 -71 -537 0.56 0.60 
300120 2.13 2.11 651 -242 1.27 7.86 
300390 0.22 0.40 -15474 44621 0.18 0.27 
300320 2.35 5.44 1928 10225 0.11 0.09 
300490 0.04 0.05 -372115 -828073 0.04 0.05 
300670 1.01 0.59 -363 -1644 0.36 0.59 
300220 0.01 0.01 -46301 -58580 0.16 0.12 
300660 0.01 0.02 791 14763 0.33 0.33 
300610 0.07 0.02 -44749 -117101 0.08 0.05 
300431 0.00 0.05 -138344 -26491 0.51 0.52 
300640 0.06 0.07 -1840 -11838 0.22 0.13 
300630 0.51 0.79 165895 319813 1.25 1.85 
300439 0.01 0.01 -63969 -103043 0.06 0.07 
300510 0.66 0.76 44887 59704 0.36 0.42 
300432 0.01 0.02 -1412 -2052 0.03 0.03 
300290 0.01 0.01 -6254 -28198 0.18 0.09 
300620 0.02 0.04 -3525 -17033 0.01 0.01 
300212 0.00 0.00 0 -131239 0.00 0.05 
300215 0.00 0.00 0 -175231 0.00 0.01 
300449 0.00 0.00 0 -3302 0.00 0.01 
300219 0.00 0.19 0 -8305 0.00 0.02 
300211 0.00 0.00 0 -14 0.00 0.00 
300213 0.00 0.00 0 -142 0.00 0.00 
300214 0.00 0.00 0 -63 0.00 0.00 
300341 0.00 0.00 14 78 0.00 0.00 
300342 0.00 0.00 14 78 0.00 0.00 
300349 0.00 0.16 0 0 0.00 0.02 
300360 0.00 0.03 0 0 0.00 0.05 
300441 0.00 0.00 -3585 -4846 0.00 0.00 
300442 0.00 0.00 -3585 -4846 0.00 0.00 
300460 0.00 2.53 0 9 0.00 0.03 
 Source: Authors’ calculation based on Trade Map (ITC, undated) 
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6. Conclusion 
One crucial objective of the Make in India initiative has been to attract foreign 
firms to establish production facility in India and transfer modern technology, so 
that domestic firms also benefit from the spillover effect in long run. The other 
goal is to reduce import dependency and enhance domestic production throughout 
the value chain, ensuring maturity of the Indian players in the process. For 
facilitating the process in manufacturing sector in general and pharma sector in 
particular, a number of steps has been undertaken in the last couple of years (GoI, 
2018). Though India offer a growing domestic market to facilitate Make in India 
scheme, export promotion would play a crucial role in realization of both the 
objectives. It is therefore imperative that India is able to extract the benefits of 
appropriate opportunities in trade arena, and the recent US tariff imposition on 
China offer India one such occasion.  
The analysis however portrays a modest opportunity for Indian pharmaceutical 
exports in the US market, based on their past performance. Only six products, 
based on the six indicators, are found to be enjoying competitiveness in the US 
market. The result can be part explained by the fact that Chinese and Indian 
pharma exports are entering US market in demarked product categories (Table 2). 
Nevertheless, the results reflect modestly on absolute performance of Indian 
pharma exports in the US market so far, despite greater focus on the sector in 
recent period. The scenario therefore pose a crucial challenge for Indian pharma 
sector. The modest performance expectation might be shaped by two broad factors. 
First, the Indian exports are intensive in generic products, rather than patented 
medicines. The scenario is not expected to change drastically, given the modest 
R&D scenario prevailing in pharma sector (Joseph, 2011). Government incentives 
to facilitate research in the pharma sector might play a crucial role in this regard. 
Second, though Indian firms have adopted the Good Manufacturing Practices 
(GMP) guidelines, compliance with the evolving standards set by US Food and 
Drug Administration (USFDA) would continue to play a crucial role. Many Indian 
products, including medicine items, have been rejected by USFDA over the last 
decade (ET, 2016; Phadnis, 2017). Therefore, developing a framework to ensure 
standard equivalence with US would be important in enhancing Indian pharma 
exports.  
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